On Tuesday, Novavax, Inc (NASDAQ: NVAX) was -5.06% drop from the session before settling in for the closing price of $7.91. A 52-week range for NVAX has been $5.01 – $11.55.
During the last 5-year period, the sales growth of Healthcare Sector giant was 25.88%. When this article was written, the company’s average yearly earnings per share was at 266.13%. With a float of $148.05 million, this company’s outstanding shares have now reached $162.16 million.
Novavax, Inc (NVAX) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Novavax, Inc stocks. The insider ownership of Novavax, Inc is 8.85%, while institutional ownership is 58.79%. The most recent insider transaction that took place on May 19 ’25, was worth 75,883. Before that another transaction happened on Apr 14 ’25, when Company’s Former Director proposed sale 4,000 for $6.10, making the entire transaction worth $24,406.
Novavax, Inc (NVAX) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.76 earnings per share (EPS) during the time that was better than consensus figure (set at -0.78) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 266.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 69.13% during the next five years compared to 25.88% growth over the previous five years of trading.
Novavax, Inc (NASDAQ: NVAX) Trading Performance Indicators
You can see what Novavax, Inc (NVAX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.34. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.26, a number that is poised to hit -1.20 in the next quarter and is forecasted to reach 0.05 in one year’s time.
Technical Analysis of Novavax, Inc (NVAX)
Looking closely at Novavax, Inc (NASDAQ: NVAX), its last 5-days average volume was 3.66 million, which is a drop from its year-to-date volume of 6.28 million. As of the previous 9 days, the stock’s Stochastic %D was 13.38%.
During the past 100 days, Novavax, Inc’s (NVAX) raw stochastic average was set at 30.57%, which indicates a significant increase from 0.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.37 in the past 14 days, which was lower than the 0.41 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.39, while its 200-day Moving Average is $7.61. However, in the short run, Novavax, Inc’s stock first resistance to watch stands at $7.75. Second resistance stands at $7.98. The third major resistance level sits at $8.11. If the price goes on to break the first support level at $7.39, it is likely to go to the next support level at $7.26. Now, if the price goes above the second support level, the third support stands at $7.03.
Novavax, Inc (NASDAQ: NVAX) Key Stats
There are 162,422K outstanding shares of the company, which has a market capitalization of 1.22 billion. As of now, sales total 682,160 K while income totals -187,500 K. Its latest quarter income was 239,240 K while its last quarter net income were 106,510 K.
